SAB Biotherapeutics, Inc.
Fully human polyclonal anti-thymocyte globulin (ATG) antibodies produced using transchromosomal bovines
- Sector
- Biotech
- Headquarters
- Sioux Falls, SD
- Founded
- 2020
- Latest Form D
- $175M, Aug 2025
- Total capital
- $186M
- Federal grants
- $3.9M
- 4 awards · 2016–2020
- Rank in peer group#247 of 514
- Private capital raised
- $183M
- 2 Form D · last Aug 2025
- 15 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 8 pending · first 2024
- Rank in peer group#186 of 514
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$175M
- Private capital raisedForm D · SEC · 1st filing$7.5M
- Federal grantHealth and Human S · Phase II · Advancing a Candidate Human Polyclonal Anti-Thymocyte Globulin Product Produced in Transchromosomal Bovine for Transplant Induction/Acute Rejection and T1D Therapy$418K
- Federal grantHealth and Human S · Phase II · Advancing a Candidate Human Polyclonal Anti-Thymocyte Globulin Product Produced in Transchromosomal Bovine for Transplant Induction/Acute Rejection and T1D Therapy$1.4M
- Federal grantHealth and Human S · Phase II · Production of therapeutic human polyclonal antibodies against influenza viruses$670K
- Federal grantHealth and Human S · Phase II · Production of therapeutic human polyclonal antibodies against influenza viruses$1.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
86months
from SAB Biotherapeutics, Inc.’s first federal award to its first private round.
- First federal award · Aug 2016
- Health and Human S · $1.4M
- First Form D · Oct 2023
- $7.5M · 1st Form D
- Awards before first raise
- 4 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#247 · top 48%
- Granted patents#186 · top 36%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Andrew MoinDirectorNamed in SEC Form D filings
- Christine HamiltonDirectorNamed in SEC Form D filings
- David Charles LinkDirectorNamed in SEC Form D filings
- Eddie SullivanExecutive Officer, DirectorNamed in SEC Form D filings
- Erick LuceraDirectorNamed in SEC Form D filings
- Jay SkylerDirectorNamed in SEC Form D filings
Show all 12 people
- Jeffrey G. SpragensDirectorNamed in SEC Form D filings
- Katie ElliasDirectorNamed in SEC Form D filings
- Russell J. BeyerExecutive OfficerNamed in SEC Form D filings
- Samuel J. ReichExecutive Officer, DirectorNamed in SEC Form D filings
- Scott J. GibersonDirectorNamed in SEC Form D filings
- William PolvinoDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 9- PendingUngulate-derived Polyclonal Immunoglobulin Specific For Coronavirus Protein And Uses ThereofUSPTOApplication 18637145
- GrantedUngulate-derived Polyclonal Immunoglobulin Specific For Coronavirus Protein And Uses ThereofUSPTOUS 11,975,066
- PendingUngulate-derived Polyclonal Immunoglobulin Specific For Coronavirus Protein And Uses ThereofUSPTOApplication 63180935
Show all 9 patent records
- Ungulate-derived Polyclonal Immunoglobulin Specific For Coronavirus Protein And Uses ThereofNov 14, 2024 · Application 18637145Pending
- Ungulate-derived Polyclonal Immunoglobulin Specific For Coronavirus Protein And Uses ThereofMay 7, 2024 · US 11,975,066Granted
- Ungulate-derived Polyclonal Immunoglobulin Specific For Coronavirus Protein And Uses ThereofApplication 63180935Pending
- Ungulate-derived Polyclonal Immunoglobulin Specific For Coronavirus Protein And Uses ThereofApplication 63144784Pending
- Ungulate-derived Polyclonal Immunoglobulin Specific For PD-L1 And Uses ThereofApplication 63113635Pending
- Ungulate-derived Polyclonal Immunoglobulin Specific For Egfr And Uses ThereofApplication 63113643Pending
- Ungulate-derived Polyclonal Immunoglobulin Specific For Coronavirus Protein And Uses ThereofApplication 63076121Pending
- Ungulate-derived Polyclonal Immunoglobulin Specific For Coronavirus Spike Protein And Uses ThereofApplication 63072683Pending
- Ungulate-derived Polyclonal Immunoglobulin Specific For Influenza Virus And Uses ThereofApplication 63284577Pending
Related companies, and why
- SAB CAPRA, LLCShares a founder: WU, HUA
- ALZARROK BIO LLCSimilar federal contract value in Biotech · null in contracts
- CRYSTAL BIOSCIENCE, INC.Similar federal contract value in Biotech · null in contracts
- Novelmed Therapeutics IncSimilar federal contract value in Biotech · null in contracts
- Atsena Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- RNA THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .